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ABSTRACT
Omega-3 polyunsaturated fatty acids (PUFAs) have well established anti-cancer 
properties. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are among 
this biologically active family of macromolecules for which various anti-cancer effects 
have been explained. These PUFAs have a high safety profile and can induce apoptosis 
and inhibit growth of cancer cells both in vitro and in vivo, following a partially selective 
manner. They also increase the efficacy of chemotherapeutic agents by increasing the 
sensitivity of different cell lines to specific anti-neoplastic drugs. Various mechanisms 
have been proposed for the anti-cancer effects of these omega-3 PUFAs; however, the 
exact mechanisms still remain unknown. While numerous studies have investigated 
the effects of DHA and EPA on solid tumors and the responsible mechanisms, there 
is no consensus regarding the effects and mechanisms of action of these two FAs in 
hematological malignancies. Here, we performed a systematic review of the beneficial 
effects of EPA and DHA on hematological cell lines as well as the findings of related 
in vivo studies and clinical trials. We summarize the key underlying mechanisms and 
the therapeutic potential of these PUFAs in the treatment of hematological cancers. 
Differential expression of apoptosis-regulating genes and Glutathione peroxidase 4 
(Gp-x4), varying abilities of different cancerous and healthy cells to metabolize EPA 
into its more active metabolites and to uptake PUFAS are among the major factors 
that determine the sensitivity of cells to DHA and EPA. Considering the abundance of 
data on the safety of these FAs and their proven anti-cancer effects in hematological 
cell lines and the lack of related human studies, further research is warranted to find 
ways of exploiting the anticancer effects of DHA and EPA in clinical settings both in 
isolation and in combination with other therapeutic regimens.
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INTRODUCTION
Omega 3 polyunsaturated fatty acids (PUFAs) are 
members of a large group of fatty acids (FAs) possessing 
multiple double bonds in their structures [1]. These 
biologically active macromolecules are well known to 
have various vital physiological roles required for proper 
functioning of cells [1]. Many effects of these FAs are 
mediated by their more active longer chain metabolites 
which act via changing the plasma membrane composition, 
producing various inflammatory mediators and altering 
the expression of different genes. Eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) are among 
the very long chain PUFAs for which various health 
benefits have been shown. These FAs decrease the risk 
of cardiovascular diseases by regulating the contributing 
risk factors including blood pressure, blood coagulation, 
cardiac rhythm and heart rate among many others [2–4]. 
Anti-inflammatory [5] and immune modulatory effects 
[1, 6] and the regulation of several metabolic pathways 
by these FAs have been also reported giving them the 
potential to be therapeutically exploited in the treatment of 
inflammatory diseases, metabolic disorders such as type-2 
diabetes and immunocompromising conditions.
An epidemiological study in 1997 revealed that 
decreased incidence of colorectal cancer among South 
African West Coast fishermen who generally had a less 
healthy diet in comparison with the urban population, 
could be attributed to presence of fish oil in their diet 
[7]. Dietary intake of omega-3 FAs has been also shown 
in human studies to inversely correlate with the overall 
risk of different types of malignancies such as colorectal, 
prostate and breast cancer [8–10]. A substantial number 
of in vitro studies on cancer cell lines as well as studies 
on animal models of cancers have shown the anti-
proliferative, apoptotic, cytotoxic, and anti-metastatic 
properties of DHA and EPA [11]. Keeping in mind that 
ROS can decrease cancer cell survival [12], different 
mechanisms have been suggested for the anti-cancer 
effects of DHA and EPA such as induction of ROS and 
consequent peroxidation of lipids [13, 14], changing 
the composition of the plasma membrane and lipid rafts 
[15, 16], affecting the mitochondrial membrane potential 
[17] and epigenetic alteration of genes involved in 
apoptosis [18].
Potential drug sensitizing effects of DHA and EPA 
have also been reported in numerous studies such that low 
amounts of these two FAs in combination with anticancer 
agents can result in increased sensitivity of cancer cells 
to anti-neoplastic agents even in some drug-resistant cell 
lines [19]. Recent evidence also points at the potent and 
at the same time selective actions of EPA and DHA on 
multiple myeloma cell lines which had not been previously 
investigated [20]. Most of the well-established anti-cancer 
effects of these PUFAs have been studied in solid tumors. 
Although ample data is available regarding the effects of 
DHA and EPA on haematological malignancies, still there 
is ambiguity regarding the exact mechanisms responsible 
for their actions on haematological cancers. In the present 
study, we systematically reviewed the effects of DHA 
and EPA on different leukemic and multiple myeloma 
cells with particular focus on the potential mechanisms of 
action. Moreover, we review the current evidence on the 
bioavailability and applicability of EPA and DHA for their 
clinical use in the context of haematological cancers.
Search strategy and data extraction
In order to access the relevant data, a literature 
search was performed based on the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines. The authors explored the Web 
of Science, Pubmed, and Scopus databases using the 
following keywords: “Leukemia” AND “DHA OR 
EPA”, “Multiple Myeloma” AND “DHA OR EPA”, 
and “Lymphoma” AND “DHA OR EPA”. EPA and 
DHA are abbreviations which are frequently used to 
show eicosapentaenoic and docosahexaenoic acids, 
respectively. In total, 674 published papers were retrieved 
after applying the filter of “articles in English only”. After 
removing the duplicates, the articles were screened based 
on their relevance to the topic and all irrelevant papers 
were excluded. The studies where the term “lymphoma” 
was detected in the context of the extended form of bcl-
2 (B cell lymphoma 2) and were found irrelevant to the 
topic were also removed. The full texts of the remaining 
papers (n=150) were further evaluated for the eligibility 
and relevance of their findings. All discrepancies were 
subjected to discussion until proper conclusions were 
made in each case. A final number of 87 articles met 
all the inclusion criteria and were found suitable to be 
reviewed (Figure 1). Data extraction was performed and 
the key findings of all previous studies were presented as 
tables and illustrations (Table 1 and Figure 1). The results 
were organized in separate sections including in vitro 
and in vivo studies and drug sensitizing effects. Finally, 
the overall results were subjected to discussion in which 
the possible mechanisms of selective action of EPA and 
DHA on neoplastic cells and the feasibility of their clinical 
usage were explained and a conclusion was finally drawn.
IN VITRO STUDIES ON EPA AND DHA
Anti-proliferative and differentiation inducing 
effects
Omega-3 FAs have been shown to have strong anti-
proliferative and differentiation promoting effects [21, 
22]. A natural lipid preparation rich in EPA and DHA 
(45.3% of the whole preparation) showed prominent 
anti-proliferative effects in promyelocytic leukemia (HL-
60) cells. Separate treatment with pure EPA and DHA 
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also inhibited the proliferation of these cells by 11.3 
and 19.3%, respectively. However, these effects were 
more pronounced when they were used in combination 
with other fatty acids such as conjugated linoleic acid 
(CLA) [23]. DHA (10-50 μM), in combination with 
As2O3, induced cell death in HTLV-1-immortalized 
cells via decreasing mitochondrial membrane potential 
in a caspase- and PARP-1-independent pathway. This 
suggested a necrotic cytotoxic effect rather than apoptotic 
cell death [24]. A study on HL-60 leukemia cells showed 
that EPA (10 μM) is a potent inducer of ROS production 
and myeloid leukemia cell differentiation which gives it 
the ability to potentiate the differentiation-inducing effect 
of 12-O-tetradecanoylphorbol-13-acetate (TPA) [25]. The 
proliferation of monocytic U937-1 cells has been also 
shown to be inhibited by EPA at a minimal concentration 
of 60 μM which was accompanied with apoptosis 
induction at higher concentrations of 120 and 240 μM. 
However, in contrast to the results of a majority of studies, 
these effects were not attributable to the well-established 
peroxidation mechanisms since the addition of antioxidant 
agents did not interfere with the anti-proliferative effects 
of EPA [26]. A previous study on the mouse myeloma cells 
(SP 2/0) had also shown that EPA (5-40 μg/mL) and to a 
lower extent DHA exert anti-proliferative effects on this 
cell type which could be roughly imputed to their lipid 
peroxidation effects. Complete blockade of this effect by 
superoxide dismutase (SOD) and cyclooxygenase and 
lipooxygenase inhibitors revealed a role for superoxides 
as well as prostaglandins and leukotrienes [27]. A study 
on HL-60 leukemia cells evaluated the effects of EPA in 
combination with linolenic acid (GLA) on pulmonary 
inflammation. EPA (50-100 μM) noticeably increased 
apoptosis and reduced cell viability in HL-60 cells. 
This was associated with a significantly enhanced rate 
of necrosis [28]. DHA (10 μM) also induced apoptosis 
and reduced cell viability in the primary cells of CLL 
patients in a concentration- and time-dependent manner 
Figure 1: Flow diagram of the search strategy.  “Leukemia” AND “DHA OR EPA” and “Multiple Myeloma” AND “DHA OR 
EPA” were searched in three databases of Web of Science, Pubmed, and Scopus. Finally 133 papers were deemed eligible to be reviewed.
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Table 1: The effects of EPA and DHA treatment on different cell lines and the suggested mechanisms
Cell line 
animal model
Specification EPA DHA Most 
effective 
dosage(s)
Incubation 
time(s)
Outcomes Reference
U 266 B lymphocyte 
(lymphoblast)
* * 50 μM
100 μM
Apoptosis induction, Drug 
sensitizing (Bortezomib), No 
effect on normal PBMCs
Caspase 3 activation, 
Hypoxia modulation, NF-kB 
inhibition, Mitochondrial 
perturbation (↑mitochondrial 
membrane potential (ΔΨm)),
Upregulation of genes 
involved in oxidative stress
[20]
L363 plasma cell 
leukemia
* *
OMP-1/2 multiple 
myeloma
* *
U937 Monocytic 
leukemia
* 10 μM
20 μM
Apoptosis induction, 
Caspase 3 activation 
and ROS generation as a 
result of: ↑[Ca2]i via PLC/
IP3 pathway and PKCγ/δ 
activation
[47]
Jurkat Human T cells * * 10 μM
20 μM
↑[PH]I, simple diffusion, 
(flip-flop) of the fatty acid, 
occurring in phospholipid 
bilayers of the plasma 
membrane (the long-lasting 
acidification was dependent 
on increases in [Ca2]i)
[48]
Molt-4 Leukemic cell 
line
* * 5-10-20 μg Antiproliferative/cytotoxic 
effect in both normal and 
leukemic lymphocytes 
(concentration dependent)
↑IL-2 (in leukemic cells), 
↓IL-2 (in normal cells), Free 
radical generation (↑SO2
- and 
lipid peroxidation (↑MDA)
[84]
HL-60 Human 
promyelocytic 
leukemia cells
* * 60 μM 6, 12 h Growth inhibition and 
apoptosis induction, ROS 
generation,
Activation of caspase-like 
proteases (3, 6, 8, and 
9-not 1), Activation of 
Bid cleavage, Decreasing 
mitochondrial membrane 
potential, Cytochrome c 
release from mitochondria, 
Surfactant effect on 
membrane
[17]
HL-60 Human 
promyelocytic 
leukemia cells
* * As parts 
of lipid 
preparations
NM Antiproliferative effect
NM
[23]
(continued)
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Cell line 
animal model
Specification EPA DHA Most 
effective 
dosage(s)
Incubation 
time(s)
Outcomes Reference
U937 promonocytic 
cell line
* 100 μM 1, 3, and 24 h Regulating gene expression
↑monocytic (leukemia) cell 
differentiation, Proliferation 
inhibition,
↑ demethylation of a specific 
CpG site in interon 1 on 
H-Ras gene,
↑H-Ras isoform mRNA and 
protein expression
↑active phosphorylated 
forms of C/EBPβ and 
ERK1/2,
↑proteins expression of 
CCAAT/enhancer-binding 
proteins (C/EBP and C/
EBP), PU.1, and c-Jun 
(myeloid lineage-specific 
transcription factors)→ 
↑expression of M-CSF 
recepror
[18, 46]
HL-60 and 
K-562
Human acute 
promyelocytic 
leukemia HL-
60 and
chronic 
myelogenous 
leukemia 
K-562 
cell lines, 
respectively
* NM 24 h Changes in cell cycle: ↑G0/
G1, ↓G2/M
↑Necrosis
↑Apoptosis (only in HL-60)
↑bcl-2 expression
[36]
HL-60 and 
K-562
Human acute 
promyelocytic 
leukemia HL-
60 and
chronic 
myelogenous 
leukemia 
K-562 
cell lines, 
respectively
* 40, 60 and 
120 μM
24 and 72 h ↑Necrosis
↑Apoptosis (only in HL-60)
Independent of DNA 
fragmentation
[38]
HL-60 Human acute 
promyelocytic 
leukemia
* 10-160 μM 24, 48 and 
72 h
↑Apoptosis
↓Proliferation
Phosphorylation-dependent 
inactivation of Rb protein
Inducing cell cycle arrest at 
G0/G1 phase
↑Expression of E2F-6 and 
Bax
[41]
(continued)
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Cell line 
animal model
Specification EPA DHA Most 
effective 
dosage(s)
Incubation 
time(s)
Outcomes Reference
CEM, HL-
60, MM1.R, 
and MM1.S
T-cell 
leukemia, 
myeloid 
leukemia, 
myeloma, and 
myeloma, 
respectively
* 100 μM 16 h ↑Sensitivity to DHA 
cytotoxic effects
↓GP-x4 expression
[66]
Raji human B-cell 
lymphoblastoid 
line
* 100 μM 72 h Synergizes the effect of 
clioquinol with regard to the 
following parameters:
↑Apoptosis
↓Cell viability
↓NF-κB activity
↓Levels of Akt, p-65 and 
Bcl-2
[68]
EHEB, 
MEC-2
JVM-2
B-CLL-
derived cell 
lines
B-PLL-derived 
cell line
* * 55, 75, and 
100 μM
72 h ↓Cell viability
↑Lipid peroxidation
↑ROS production
Cell cycle arrest in G2/M
[85]
C57/BL6 
mouse
Receiving 
transplantation 
of HSCs 
expressing 
Bcr-Abl (CML 
model)
AML model
* 1.8% of total 
diet energy
8 weeks ↓LSC population
↓Leukocytosis
↓Splenomegaly
↓Leukemia burden
Via production of Δ12-PGJ3
Blocked by indomethacin 
and HQL-79
[52]
U937-1 Monocytic cell 
line
* 60, 120 and 
240 μM
72 h ↓ Cell viability and 
proliferation (60 μM), 
↑Apoptosis (120 and 240 
μM),
↑Lipid droplet accumulation, 
↑CD23 expression,
Lipid peroxidation-
independent mechanisms
[26]
Raji, Ramos, 
U937-GTB, 
U937-1 and 
Mono Mac-6
Highly 
sensitive
* * 30, 60 and 
120 μM
24 h and 72 h ↑ Apoptosis and necrosis 
(EPA)
↓ Cell multiplication
↑TAG-rich lipid droplets 
(EPA)
↑Lipid peroxidation
Reversible by Vitamin E
[40, 71]
Reh, Molt-
4, Jurkat, 
K-562, and 
KG1-a
Moderately 
sensitive
* * 50 and 120 
μM
KM-3, Nalm-
6 and THP-1
Slightly 
sensitive
* * 120 μM
(continued)
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Cell line 
animal model
Specification EPA DHA Most 
effective 
dosage(s)
Incubation 
time(s)
Outcomes Reference
HL-60 * 60 μM 72 h ↑Apoptosis (19%), ↑Necrosis 
(32%), ↓Proliferation, 
↑Differentiation,
↑Lipid peroxidation, 
↑Serglycin mRNA levels, 
↑Production of superoxide 
anions, ↑G1 phase 
prolongation
[39]
HL-60 Human 
promyelocytic 
leukemia
* 10, 20, 50, 
and 100 μM
2, 4, 8, 12, 
and 24 h
↓Cell viability, ↑Apoptosis, 
↑Necrosis, Induction of 
apoptosis by select dietary 
n-3 (EPA) and n-6 (GLA) 
polyunsaturated fatty acids
[28]
ATCC, CRL-
1923
Chronic 
lymphocytic 
leukemia
* 10 μM 24 and 48 h ↓Cell viability, ↑Apoptosis, 
↑Lipid peroxidation and 
generation of reactive 
oxygen species, ↓Activation 
of NF-κB, Exerts anti-
inflammatory effects after 
linking to the G protein-
coupled receptor 120 in 
macrophages
[29]
Ramos and 
Jurkat cells
* 30 μM 24 h ↑ Caspase 3 and 9 activities [31]
HL-60 Human 
promyelocytic 
leukemia
* 0.4, 2, 5 and 
10 μM
24 h ↓Sphingosine-induced 
apoptosis
Inhibition of cytosolic 
phospholipase A2
[30]
RBL2H3, 
HeLa
* 25, 50, 75 
and 100 μM
18 h ↑Apoptosis, ↑ Release of 
Cytochrome c, ↑Activation 
of caspase-3,
↑Hydroperoxide in 
mitochondria
[32]
HL-60 Human 
promyelocytic 
leukemia
* 50 μM 24 h ↑Apoptosis, ↑Activation of 
caspase-3, Bax-independent 
pathway
[34]
RBL2H3 Rat basophilic 
leukemia cells
* 50 μM 4 h Increase calcium 
level, Generation of 
hydroperoxide,
Induce apoptosis via 
Calcium-dependent 
hydroperoxide accumulation,
[33]
HL-60 Human 
promyelocytic 
leukemia
* 50 μM 24 h ↑Cell differentiation, 
↑Growth inhibition, 
↑NBT reducing activity, 
↑Expression of c-jun mRNA, 
↑ c-jun protein, ↓ Expression 
of c-myc oncogene
[35]
(continued)
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[29]. Conversely, in another study, DHA (10 μM) 
prevented sphingosine-induced apoptosis in HL-60 cells 
after 24 h [30]. Following EPA (30 μM) treatment, the 
cells showed increased caspase 3 and 9 activity without 
affecting caspase 8 activity or cell cycle progression [31]. 
Similar results have shown that EPA induces apoptosis via 
Cell line 
animal model
Specification EPA DHA Most 
effective 
dosage(s)
Incubation 
time(s)
Outcomes Reference
RBL2H3 Rat basophilic 
leukemia cells
* * 25, 50, 75 
and 100 μM
1 h Suppress Th-2-seweked 
allergic immune responces, 
↓Il-4 and IL-13 production, 
↓ c-Fos expression, 
↓NF-AT expression, 
↓ Phosphorylation of 
extracellular signal-related 
kinase, ↓Phosphorylation 
of p38 mitogen-activated 
protein kinase by DHA only.
[44]
Jurkat Human T cells * 10 μM 3, 6, 12, and 
24 h
↑Apoptosis, Cell cycle arrest
↑Ceramide levels → cdk2 
inhibition → ↑PPa and PP2A 
activities → ↓Rb protein 
phosphorylation
[43]
Jurkat Human T cells * 60 and 90 
μM
48 and 24 h, 
respectively
↑Apoptosis
Caspase-3 cleavage, PARP 
degradation, and DNA 
fragmentation
(via a phosphatase mediated 
process involving PP1 and 
PP2B)
[42]
Jurkat Human T cells * 15 μM 2 h ↓ viability, Caspase-3 
activation, PP1-mediated
[7]
HL-60 Human 
promyelocytic 
leukemia
* 20, 35, and 
70 μM
48 h ↓ proliferation, ↑Apoptosis
Depletion of intracellular 
Ca++ → ER stress → UPR 
response (↑ protein levels of 
phosphorylated Eukaryote 
translation initiation factor 
2a, a UPR hallmark)
[9]
SP 2/0 Mouse 
myeloma cells
* * 5, 10, 20, 
and 40 μg/ml
24, 48, 72 h ↓ proliferation, ↓ Viability, 
Superoxides, prostaglandin 
and leukotriene-dependent
[27]
T27A Mouse 
leukemia cell 
line
* 200-400 μM
1 mM
NM Cytotoxicity
↑ tumor cell and lipid vesicle 
premeability
[86]
HL-60 Human 
promyelocytic 
leukemia
* 20, 40, 60, 
and 80 μM
24 h ↓ proliferation, ↑Apoptosis, 
Inhibition of topoisomerases 
I and II and DNA 
polymerases, Cell cycle 
arrest at G1/S phase, ↑Cyclin 
A and E protein levels
[87]
HSC, Hematopoetic Stem Cell; LSC, Leukemia Stem Cell; TAG, triacylglycerol; cdk2, cyclin-dependent kinase 2; Rb, 
retinoblastoma; NBT, Nitroblue Tetrazolium;
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increased release of cytochrome c, activation of caspase-3 
and enhanced mitochondrial-derived hydroperoxide 
(mitochondrial oxidative stress) [32]. To further 
investigate the mechanisms of EPA-induced apoptosis 
in mitochondria, RBL2H3 cells were treated with 50 μM 
EPA for 4 h. This significantly increased mitochondrial 
oxidative stress and calcium levels. The results showed 
that EPA can induce apoptosis via calcium-dependent 
hydroperoxide accumulation in the mitochondria [33].
Significant caspase-3 dependent apoptosis was 
observed following DHA (50 μM) treatment in HL-60 cells. 
The use of cyclosporine-A as a mitochondrial permeability 
transition pore (MPTP) inhibitor did not inhibit caspase-3 
activation or Bax translocation indicating that DHA may 
induce apoptosis through a Bax-independent pathway [34]. 
Treatment of HL-60 cells with 50 μM DHA resulted in a 
concentration-dependent increase in cell differentiation and 
inhibited the cell growth. It also enhanced the nitro blue 
tetrazolium chloride (NBT) reducing activity as an indicator 
of cell differentiation. In addition, DHA (50 μM) noticeably 
increased c-jun mRNA and protein levels whilst those of 
c-myc were markedly reduced [35].
Apoptotic effects
In vitro treatment of HL-60 and K-562 cells 
with EPA delayed cell cycle progression at G0/G1 but 
shortened the G2/M duration. It also induced significant 
necrosis in both cell lines by 19.6 and 4.4%, respectively. 
Moreover, apoptosis was induced by EPA to a much 
greater extent in HL-60 cells which was mediated mainly 
by downregulating the expression of the bcl-2 signalling 
molecule, a major regulator of apoptosis [36, 37]). Similar 
results were reported in another study indicating that EPA 
(40, 60, and 120 μM) can induce apoptosis in HL-60 cells 
but not in K562 cells independent of any of its effects on 
DNA fragmentation [38]. In addition, the apoptotic and 
necrotic effects of EPA have also been reported to be 
independent of both cyclooxygenase and lipooxygenase 
pathways and of lipid peroxidation [39]. Although the 
various EPA-sensitive and EPA-resistant leukemic cell 
lines express different levels of pro-apoptotic and anti-
apoptotic factors such as c-myc and Bcl-2, the differences 
in the expression of these factors do not account for its 
differential effects on apoptosis of different cells [40].
DHA from sources other than fish oil such as 
Crypthecodinium cohnii algae also have notable cell 
growth inhibiting properties in HL-60 cells. Algae-derived 
DHA halted HL-60 cell proliferation by delaying the cells 
in G0/G1 in a concentration-dependent fashion (IC50 of 
74 μM) and significant apoptosis was observed at 24, 
48, and 72 h. This was associated with the inactivation 
of retinoblastoma (Rb) protein and up-regulating the 
expression of E2F-6, a suppressor of transcription, and 
the pro-apoptotic molecule Bax [41]. High concentrations 
of DHA (60 and 90 μM) induced Jurkat cell apoptosis 
via caspase 3 activation, PARP degradation and DNA 
fragmentation.
Tautomycin and cypermethrin, two phosphatase 
inhibitors which inhibit protein phosphatase 1 (PP1) and 
protein phosphatase 2B (PP2B) respectively, ablated the 
apoptotic effect of DHA implying a role for PP1 and 
PP2B in the induction of apoptosis [42]. The phosphatase-
dependent cytotoxic effect of DHA (15 μM) has been 
also previously revealed in another study in which 
phosphatidic acid (PA), a specific PP1 inhibitor, reversed 
the DHA-induced apoptosis in Jurkat cells [7]. Repeated 
exposure to low concentrations of DHA (10 μM) rapidly 
decreased Jurkat cell viability whilst a single exposure 
at the same concentration only induced cell cycle arrest. 
Overall, DHA-induced Jurkat cell apoptosis and loss 
of proliferation are believed to result from increased 
ceramide production which leads to the decreased cyclin-
dependent kinase 2 (cdk2) activity as well as increased 
PP1 and PP2A activities. This leads to the inhibition of 
Rb phosphorylation and subsequent cell growth arrest 
[43]. An overview of the effects of EPA and DHA in 
hematological cancers is illustrated in Figure 2.
Integration of EPA and/or DHA into the plasma 
membrane of cells decreases the proportion of arachidonic 
acid (AA) and consequently the production of AA-derived 
inflammatory mediators. In turn, the production of the 
less inflammatory EPA- and DHA-derived eicosanoids 
is increased. On the other hand, the ability of these two 
FAs to decrease the activity of regulatory T cells, major 
regulators of immune responses to leukemic cells, 
skews the immune response to act against hematological 
malignancies [11]. DHA and EPA can also prevent allergic 
diseases by inhibiting Th2-driven immune responses. 
The results showed that they mitigate IL-4 and IL-13 
production, decrease expression of c-Fos and NF-AT 
whilst inhibiting phosphorylation of the extracellular 
signal-related kinase [44].
Epigenetic alterations
DHA and EPA might also exert their biological 
effects via induction of epigenetic changes. These FAs 
are able to target the aberrant DNA methylation which 
is present in all types of cancers either across the whole 
DNA or at specific sites such as the non-coding regions 
of tumor suppressor genes [45]. Alteration of the extent 
of CpG methylation by PUFAs results in changes in the 
pattern of gene silencing and consequently the fate of 
target cell transcription. For example, EPA (100 μM) 
demethylates specific CpG sites within the promoter 
region of the tumor suppressor gene CCAAT/enhancer-
binding protein (C/EBP)δ in the U937 promonocytic cell 
line leading to its enhanced expression. In addition, EPA 
and to lower extents other PUFAs such as DHA, increased 
the expression of transcription factors including C/EBPβ 
and C/EBPδ, PU.1 and c-Jun via similar epigenetic 
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mechanisms [46]. Treatment of U937 cells with EPA (100 
μM) can also activate the Ras/ERK/C/EBPβ pathway via 
demethylating a CpG island within an intron of the H-Ras 
gene which drives monocyte differentiation [18]. Overall, 
the anti-proliferative and differentiation promoting effects 
of EPA on monocytic leukemia cells is driven, at least 
in part, by demethylation of promoter regions of genes 
involved in tumor suppression and differentiation. These 
effects are not restricted to EPA as they also occur, albeit 
at lower potencies, with other PUFAs. EPA-induced 
down-regulation of serglycin mRNA is involved in HL-60 
cell differentiation in a similar manner to that evoked by 
retinoic acid (RA). Nonetheless, this effect was not via 
actions on c-myc expression, a known mechanism of RA-
induced differentiation [39]. In contrast, EPA treatment 
of U-937-1 cells does not increase the expression of the 
monocytic lineage differentiation markers, CD36 and 
CD68, at least at the concentrations tested [26].
Effects on calcium homeostasis
DHA (10 and 20 μM) activates the PLC/IP3 pathway 
and thereby increases intracellular calcium (CA++) 
concentration and this has been implicated in DHA-
induced apoptosis in U937 cells [47]. Ca++ mobilization 
by DHA also decreases intracellular pH which might play 
a role in DHA-mediated apoptosis and anti-proliferative 
effects in human T cells [48]. Econazole is an antifungal 
agent which mobilizes the endoplasmic reticulum (ER) 
Ca++ storage and blocks extracellular Ca++ influx leading to 
a constant depletion of ER Ca++ storage [49, 50]. In HL-60 
cells, EPA induces apoptosis via the induction of ER stress 
causing the unfolded protein response (UPR) pathway to 
be activated. EPA triggers ER-stress via the depletion of 
intracellular Ca++ levels with a mechanism similar to that 
of econazole. In a similar fashion, EPA not only blocks 
trans-membrane Ca++ influx via store-operated Ca++ 
channels (SOC), but also it increases Ca++ release from 
the ER in an IP3-independent pathway. This will trigger 
the UPR response and finally lead to apoptosis [9].
IN VIVO STUDIES
Dietary supplementation of 1.5% DHA (as 
an adjuvant to the nucleoside chemotherapy drug 
Figure 2: Schematic view of the mechanisms by which EPA and DHA affect leukemic cells. Arrows show positive effect or 
activation. Dead-end lines indicate a negative effect or blockade. Question marks show controversial results from different studies. EPA 
and DHA exert their effects on cancer cells via changing the membrane compisition, altering intracellular Ca++ concentrations as well as 
intracellular PH, modifying mitochondrial membrane premeability, changing cellular resistance to ROS damage, and by direct actions on 
DNA and gene expression.
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arabinosylcytosine, AraC) into a low-fat diet resulted 
in an average daily intake of 1.8 g DHA/kgBW/day and 
significantly increased the survival time of BDF1 mice 
bearing L1210 cell-induced leukemia from 12 days post 
leukemic cell injection to 33.3 days. In contrast, animals 
receiving higher amounts of DHA (4.5 g DHA/kgBW/day) 
survived for 26.5 days after leukemia implementation 
[51]. This indicates that there is an optimal dose of 
DHA required to enhance survival time. Dietary EPA 
supplementation in experimental CML and AML C57/
BL6 mouse models has also been reported to target 
leukemia stem cells (LSCs) and decrease leukemia 
burden. Cyclooxygenase is necessary for the conversion 
of EPA into its metabolite Δ12-PGJ3. The inhibition 
of cyclooxygenase and hematopoietic prostaglandin 
D synthase (H-PGDS), by indomethacin and HQL-79 
respectively, blocked the ability of EPA to attenuate cancer 
in CML-bearing animals. This suggests that Δ12-PGJ3 is 
the active agent for the EPA-induced effects which was 
confirmed with the re-establishment of the beneficial 
effects of EPA in indomethacin-treated mice following the 
administration of Δ12-PGJ3 [52].
Effects of EPA/DHA on lymphoma cells
In a study by Speizer et al. which investigated 
the effects of fish oil FAs including EPA and DHA on 
the activity of protein kinases from lymphoma cells 
and bovine brain it was revealed that these FAs can 
differentially alter the activities of protein kinase C and 
cAMP-dependent protein kinase and thus are able to act 
as intracellular second messengers [53]. It is interesting 
to note that although EPA and DHA have been shown 
to enhance the number and function of B lymphocytes 
under normal conditions via altering the membrane 
composition of the cells, they have no such effects on 
Raji, Ramos, and RPMI lymphoma cell lines at least 
at the tested concentration (25 μM) and thus treatment 
with these two FAs does not promote cancer cell growth 
[54]. The suggested mechanism for this difference is the 
elongation of membrane-incorporated EPA and DHA into 
docosapentaenoic acid (DPA) which has been recently 
shown to substantially affect membrane properties [54]. 
EPA and more potently DHA were shown to readily 
incorporate into the plasma membrane of L5178Y 
lymphoma cells when added to the culture medium at 
concentrations higher than 10 μM. EPA and DHA also 
reduced the proliferation of the cells and increased the 
cytotoxicity of the chemotherapeutic agents including 
doxorubicin, dexamethasone, and mitomycin-C [55]. 
One study showed the necrosis and apoptosis inducing 
effects of EPA in two lymphoma cell lines, Raji and 
Ramos. The necrotic effect of EPA was reversed using 
different antioxidants without any effect on its apoptotic 
effects indicating a role for oxidative stress as a means of 
necrosis induction by EPA. In addition, protein synthesis 
was suggested to play roles in the EPA-induced apoptosis 
as this was prevented by the protein synthesis inhibitor 
cycloheximide [56]. Another study by the same group 
investigated the effects of EPA on the activities of different 
caspases and showed that the EPA-induced apoptosis in 
Ramos cells is mediated by a direct effect of EPA on the 
intrinsic pathway of apoptosis rather than interfering 
with cell cycle progression [57]. The use of triacsin C, 
an Acyl-CoA synthetase (ACS) inhibitor, has revealed 
the important role of ACS in the EPA-induced apoptosis. 
Inhibition of ACS by triacsin C caused a 90% decrease in 
the induction of apoptosis by EPA in the Ramos cell line. 
This can also, at least partly, explain the resistance of the 
U-698 cell line against EPA, since the U-698 cells express 
lower levels of ACS, compared to the EPA-sensitive cell 
lines such as Ramos [58].
A fish oil-supplemented diet has been shown 
to improve the metabolic parameters of dogs with 
lymphoblastic lymphoma. Such a diet resulted in increased 
plasma levels of DHA and EPA which was associated 
with lower levels of plasma lactic acid. This, in turn, 
increased the disease-free interval and survival time after 
doxorubicin chemotherapy [59]. The increased survival 
time and quality of life may not only have arisen from 
the direct anti-tumor activity of EPA and DHA, but also 
may be due to the cachexia-inhibiting effect of EPA, 
which was mediated by inhibition of cAMP in cancer 
cells both in mouse models and humans [60]. EPA, a key 
regulator of cyclin D1 synthesis, has been suggested to 
be of therapeutic potential in patients with mantle cell 
lymphoma since the main culprit in the pathogenesis 
and refractoriness of this type of malignancy is the 
elevated levels of cyclin D1 which is crucial in cell cycle 
progression from G1 to the S phase [61, 62]. This notion 
is further supported by the results of a study by Cvetkovic 
et al. which showed lower levels of PUFAs in the serum 
of patients with non-Hodgkin lymphoma in comparison 
with healthy controls and the association of lower amounts 
of PUFAs in the serum of these patients with the clinical 
severity and aggressiveness of the disease [63]. In vitro 
treatment of YAC-1 lymphoma cell line with EPA has been 
shown to induce apoptosis in these cells via a caspase-3 
independent pathway. Increases in the cellular ROS 
production as well as the accumulation of lipid droplets 
containing triacylglycerol in the cells were among the 
important changes observed in the YAC-1 cells treated 
with EPA [64].
DRUG SENSITIZING EFFECTS
Co-treatment of HL-60 leukemic cells with lipid 
preparations containing high concentrations of DHA 
and EPA did not improve the anti-proliferative effect of 
doxorubicin [23]. However, combining As2O3 and IFN-γ, a 
common chemotherapy for adult T-cell leukemia/lymphoma 
(ATL) patients, with emodin (a natural ROS-producing 
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agent) and 10 μM DHA resulted in a 100-fold reduction 
in the dose of As2O3 required for the effective treatment of 
ATL. Emodin and DHA have been suggested to act via a 
synergistic action with A2O3 rather than having a direct anti-
tumor action since treatment with emodin+DHA together 
did not induce significant effects on ATL. Potentiation of the 
cytostatic property of As2O3 by DHA was mainly attributed 
to its ROS generating abilities and down regulation of AP-1 
and AKT expression which are both involved in cell survival 
[24]. As2O3, as an ROS-generating anti-cancer chemical, 
enhances ROS within malignant cells which, in turn, affects 
the co-administered DHA to form fatty acid hydroxides and 
hydroperoxides [65]. This potentiates the oxidizing actions 
of As2O3 which can be exploited to combat the malignant 
cells. In support of this, incorporation of 1 and 25 μM 
DHA into an As2O3-based regimen not only extended its 
apoptotic effect to the As2O3-resistant HL-60 cell line but 
also significantly decreased the viability of leukemic cells 
when compared to DHA treatment alone [14].
On the other side, there are various defence 
mechanisms by which cells protect themselves against 
oxidative stress. Glutathione peroxidase 4 (Gp-x4) is the 
most important and the only enzyme which neutralizes 
lipid hydroperoxide, an important DHA oxidation end 
product, which mediates the cytotoxic effects of DHA 
[66]. In vivo treatment of BDF1 leukemic mice with oral 
DHA increased the cytostatic effect of AraC but also 
abolished drug toxicity-induced death. Interestingly, this 
effect was reversed when the intake of DHA was increased 
from 1.8 g to 4.5 g/kgBW/day [51].
The biological effect of each member of PUFAs is 
specific to that member and differences between members 
of the same family of fatty acids have been reported. 
In this regard, treatment of HL-60 cells, bearing a Bcr-
Abl translocation, with different concentrations of DHA 
(25, 50 and 100 μM) resulted in higher sensitivity of the 
cells to the tyrosine kinase inhibitor imatinib mesylate, 
increased percentage of apoptotic cells and reduced 
viability. In contrast, EPA, a member of the same FA 
family, had no effect at any of the concentrations tested. 
Loss of membrane integrity as well as increased DNA 
fragmentation was suggested to be involved in these 
effects [65]. Pre-incubation of the lymphoma cell line 
L5178Y with 10 μM and higher concentrations of DHA 
and EPA has been also shown to significantly increase 
the response of the cells to doxorubicin. The degree 
of unsaturation and chain length positively correlated 
with higher cytotoxic potencies of the tested FAs [55]. 
Cvetkovic et al. showed that the plasma phospholipid 
profile of patients with non-Hodgkin lymphoma influences 
response to chemotherapy in a manner that the plasma 
contents of PUFAs including EPA and DHA were lower 
in the patients who could not complete the chemotherapy 
course and in those with progressive disease compared to 
the patients in which the treatment period was successfully 
completed and remission was achieved [67].
Clioquinol, a recently used microbial agent in anti-
tumor therapy, enhanced the apoptotic effect of DHA (100 
μM) in a human B-cell lymphoblastoid line (Raji) after 
a 72 h combination therapy. Downregulation of NF-kB 
as well as reducing the levels of cell survival signalling 
molecules including Akt and Bcl-2 are involved in this 
synergistic effect. Although clinoquinol treatment alone 
did not induce lipid peroxidation, pre-treatment with 
vitamin E blocked the synergistic effect of DHA and 
clioquinol, indicating that lipid peroxidation might play a 
key role in DHA-induced toxicity in Raji cells [68].
Pre-treatment of B-CLL and B-PLL-derived cell 
lines (EHEB, MEC-2 and JVM-2, respectively) with 
different concentrations of EPA and DHA decreased the 
tolerance of the cells against doxorubicine-, fludarabine- 
and vincristine-induced toxicities resulting in decreased 
cell viability. The number of apoptotic cells also increased 
indicating that pre-treatment of the cells with DHA and 
EPA potentiated the cytotoxicity of the drugs via increasing 
lipid peroxidation, induction of ROS and inhibition of cell 
cycle at G0/M. Preventing oxidative stress using vitamin 
E did not reverse the drug-sensitizing effects suggesting 
the involvement of other unknown mechanisms [68]. 
DHA is also able to enhance doxorubicin sensitivity in 
P388 cells by elevating doxorubicin accumulation in 
cancer cells leading to increased cytotoxicity. A role for 
ROS was invoked as 50 μM DHA enhanced superoxide 
dismutase (SOD) and catalase (CAT) activities [69]. 
The drug-sensitizing effects of EPA and DHA have been 
summarized in Table 2.
DISCUSSION
Mechanisms of selective action
Although structurally similar, EPA and DHA can 
differentially affect the biological activity of cells, at least 
partly, due to their different magnitude of effects on AA-
dependent processes within cells, as evidenced in U937 
lymphoma cell line [70]. The long-term consumption of 
EPA has been shown to dramatically increase the EPA 
content of plasma, platelets and red blood cells with no 
effect on DHA content. This may suggests that extremely 
complex and distinct pathways may exist that regulate 
the metabolism of these two FAs [61]. Nonetheless, both 
EPA and DHA have selective actions on malignant cells 
with minor, if any, effects on normal cells [13, 14, 20, 24]. 
Therefore, the mechanisms responsible for these selective 
actions will not only help us design more effective anti-
cancer treatments using omega-3 FAs but may also reveal 
new targets for chemotherapeutic agents. In contrast, 
cancer cell lines show variable levels of sensitivity to 
omega-3 FAs and some of them can tolerate treatment 
with these agents and are therefore resistant to them [40]. 
However, DHA and EPA can enhance the actions of other 
drugs to modulate the dysregulated activity/expression of 
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oncogenic targets without having any significant effect on 
the target cells per se. An example of this is the ability 
of DHA and emodin to down-regulate the enhanced 
expression of AP-1 and increased AKT activity in HTLV-1 
infected T cells [24]. Furthermore, since FAs synergize the 
oxidative effects of ROS-producing agents [13, 14] this 
may also elicit a potent anti-tumor action. However, the 
effectiveness of a single administration of DHA/EPA in 
the absence of ROS-producing agents indicates that this 
cannot be the only mechanism involved.
One of the mechanisms proposed for the anti-
cancer effects of EPA and DHA is the induction of lipid 
peroxidation. The main intracellular mechanism which 
protects cells against lipid peroxidation is the enzyme 
GP-x4 and the variable sensitivity of different cell lines 
to DHA and EPA might reflect the differential expression 
of GP-x4 in various healthy and neoplastic cells. This 
will impact on the ability to protect against peroxidation-
induced cellular damage [66].
The ability of different cells to metabolize EPA 
into its more effective metabolite Δ12-PGJ3 might 
also determine cell sensitivity to this FA [52]. Elevated 
expression of 3 acyl-CoA synthetases (ACSs) is observed 
in EPA-sensitive cell lines such as Ramos and Raji, giving 
these cells a greater ability to covert EPA into its active 
form EPA-CoA. In addition, some EPA-resistant cells such 
as U-698 have a limited ability to uptake PUFAs leading 
to reduced accumulation of cytosolic lipid droplets, a 
characteristic of responsive cells [26, 71]. The differential 
expression of apoptosis regulating genes such as c-myc 
which drives the cell towards a programmed cell death 
response in those which express higher levels of c-myc 
(Ramos cell line) or towards necrotic cell death in those 
with less c-myc may explain why some neoplastic cells 
treated with EPA/DHA undergo apoptosis and others 
undergo necrosis [40].
DHA alters the composition of membrane micro-
domains replacing other fatty acids and reducing 
cholesterol and monoenoic FAs. This has been shown 
by evaluating the FA content of exfoliated microvesicles 
derived from DHA-treated leukemic cell lines. Thereby, 
DHA can induce a unique arrangement of lipid 
microdomains which might consequently determine 
the fate of membrane-bound signalling compartments 
to activate specific downstream pathways giving rise to 
different vital changes inside the cell [72].
Feasibility of clinical usage
The significant anti-cancer properties of omega-3 
FAs especially EPA and DHA as well as their selective 
action and high safety profile [73, 74] suggest a promising 
clinical future. To date, studies have investigated the 
correlation between fish oil, as a rich source of omega-3 
FAs, and other seafood consumption with a reduced 
risk of cancers. However, few clinical trials have been 
conducted to specifically study the effects of EPA and 
DHA on hematological malignancies. A clinical trial on 
12 ALL and 6 AML patients investigated the effects of 
EPA as part of an energy and protein dense supplement. At 
the end of the trial, alleviation of cancer-induced weight 
loss and improvement of the overall conditions of adult 
and pediatric patients was observed. Decrease in the levels 
of circulating cytokines and acute phase proteins were 
attributed to the desirable effects of EPA [75].
The results of phase I and II clinical trials in 
patients with solid tumors have demonstrated that 
omega-3 FAs are safe and show promising results 
especially in patients in which the blood concentration 
of these FAs was raised significantly after treatment 
[76]. The recommended dose of EPA to improve cancer-
induced cachexia is 1.5-2 g/day and side effects at this 
dose are minimal [77]; however, the benefit of increasing 
doses is unclear [78, 79]. Although criticized by the fact 
that PUFAs increase oxidative stress and the production 
of lipid peroxyl radicals within cells predisposing them 
to oxidative damage [80], the consumption of PUFAs has 
been shown to be clinically safe. In one study, the safety 
of EPA oil was compared in vivo with the conventional 
commercial fish oil and the in vitro toxicity of EPA 
was assessed as well using the Ames mutagenicity test. 
The results showed that exposure of rats for 28 days at 
doses up to 2820 mg/kg/day does not cause any adverse 
effects on either of clinical, nutritional or anatomic 
pathology parameters of the animals. Moreover, EPA 
did not induce any mutations in the Ames test [81]. 
DHA is well-tolerated by humans even at doses up to 
18 g/day [78]. In a study by Horrobin et al., the long-
term intake of 12 g/day of ethyl-eicosapentaenoate as 
a dietary source of purified EPA by a patient suffering 
mantle cell lymphoma which resulted in a cumulative 
dose of 5 kg EPA within a 16-month period was shown 
to be safe without any side effects [61]. In vitro studies 
investigating the effects of DHA on different cancer cell 
lines have indicated IC50 concentrationsof 80-90 mM 
[66] which is within the plasma and tissue concentration 
ranges of EPA/DHA and can be achieved clinically. 
Enhanced efficacy may be obtained using albumin-bound 
EPA or DHA to negate the effects of protein binding [40]. 
Moreover, it has been shown that dietary EPA, when it is 
metabolized, can produce sufficient amounts of Δ12-PGJ3 
to induce apoptosis in leukemia cells [82]. A very recent 
study which investigated the effects of dietary EPA and 
DHA supplementation on the nutritional inflammatory 
status and long-term survival of patients with acute and 
chronic leukemia and lymphomas (Hodgkin and Non-
Hodgkin lymphomas) receiving chemotherapy revealed 
that the consumption 2 g/day of fish oil (containing EPA 
and DHA) for 9 months resulted in greater reduction in 
the C-reactive protein (CRP) and CRP/albumin ratio in 
the patients receiving the supplement and chemotherapy 
in comparison to those receiving chemotherapy only. 
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This significantly prolonged the overall survival time of 
the patients [83]. The results of these studies all together 
may give rise to the notion that supplementation with 
PUFAs may not only cause direct anti-tumor effects in 
the context of haematological malignancies, but also 
it may improve the response to treatment and the side 
effects of conventional chemotherapy via attenuating the 
inflammatory status of the patients, thus playing a dual 
role in improving the treatment outcome of patients with 
haematological malignancies.
CONCLUSION
Based on the previous findings, conducting studies 
comparing different cell lines in terms of resistance and 
sensitivity to EPA/DHA is recommended. This can help 
pointing out the differences which might serve as the target 
for the action of EPA/DHA. Moreover, considering the 
diverse effects observed with high and low concentrations of 
these two FAs, determining the optimal dietary/non-dietary 
supplementation of PUFAs into chemotherapy regimens is 
Table 2: The drug sensitizing effects of EPA and DHA in combination with conventional chemotherapeutic drugs 
used for the treatment of haematological malignancies
DHA EPA Type of malignancy/model Chemotherapy drug Effect and suggested 
mechanism
Reference
* * Multiple myeloma cell lines Bortezomib (Valcane) NM [20]
* arsenic trioxide–resistant 
leukemic HL-60 cells
(as well as solid tumor cell lines)
As2O3
[A ROS inducing 
chemotherapy agent]
↑Bax expression
↑Caspase 3 activation
↑ROS production and 
lipid peroxidation
[Selective effect]
[13, 14]
* HTLV-I–immortalized
and –transformed T cells
(a model of ATL)
As2O3 ↑Cell death, 
↓Proliferation, ↑ROS 
production
↓ mitochondrial 
membrane potential
Down regulation 
of AP-1 and AKT 
expression
[Selective; only 
marginal effect on 
healthy PBMCS]
[24]
* BDF1 mice bearing L1210 
leukemic cells
AraC ↑Survival time in
↓Drug-toxicity 
induced death
[51]
* HL-60 myeloid leukemia cell line TPA ↑ROS production and 
NBT reduction
↑Differentiation of 
myeloid leukemia 
cells
[25]
* Bcr-Abl expressing HL-60 cells Imatinib ↓Viability, ↑Apoptosis, 
↓Membrane integrity, 
↑DNA fragmentation
[65]
* * B-CLL-derived cell lines EHEB 
and MEC-2
B-PLL-derived cell line JVM-2
Doxorubicin ↓Viability, ↑Apoptosis
↑ROS production
↑Lipid peroxidation
[85]
Fludarabine
Vincristine
* T27A (murine leukemia cell line) methotrexate Growth inhibition via 
synergistic effect
As2O3, Arsenic trioxide; ATL, Acute T-cell Leukemia; AraC, Arabinosylcytosine; TPA, 12-O-tetradecanoylphorbol-13-
acetate; NM, not mentioned
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also essential. Delineating the precise mechanism of action 
of EPA and DHA in inducing selective cancer cell death; 
epigenetic effects on tumor suppressor genes, enhancing 
ROS production or effects on lipid peroxidation will enable 
better targeting of cancers using these drugs. While most in 
vitro studies conducted to date focus on the direct effects of 
PUFAs, in vivo studies utilising the synergistic actions of 
EPA and DHA may shed light on the indirect mechanisms of 
these agents such as on immune cell and cytokine regulation 
which might inhibit the growth of cancer cells. Rapid 
screening of primary cancer cells exposed to DHA and EPA 
ex vivo may also define the correct patient and combination 
of drugs required for optimal therapy enhancing our options 
for personalised or precision medicine.
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